The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Advances in the medical treatment of Cushing's syndrome
Abstract
Cushing's syndrome is associated with multisystem morbidity and, when suboptimally treated, increased mortality. Medical therapy is an option for patients if surgery is not successful and can be classified into pituitary-directed drugs, steroid synthesis inhibitors, and glucocorticoid receptor antagonists. In the last decade there have been new developments in each drug category. Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients. Potential new targets in corticotroph adenomas include the epidermal growth factor receptor, cyclin-dependent kinases, and heat shock protein 90. Osilodrostat and levoketoconazole are new inhibitors of steroidogenesis and are currently being evaluated in multicentre trials. CORT125134 is a new selective glucocorticoid receptor antagonist under investigation. We summarise the drug therapies for various forms of Cushing's syndrome and focus on emerging drugs and drug targets that have the potential for new and effective tailor-made pharmacotherapy for patients with Cushing's syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Self-citationFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Cushing’s Syndrome during Pregnancy: Personal Experience and Review of the Literature
Lindsay, J. R., Jonklaas, J., Oldfield, E. H., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2361 · Cited by 343
Self-citationVerhelst, J. A., Trainer, P. J., Howlett, T. A., Perry, L., Rees, L. H., Grossman, A. B., Wass, J. A. H., & Sesser, G. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03517.x · Cited by 308
Ketoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278
Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome.
Lacroix, A., Hamet, P., & Boutin, J.-M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412104 · Cited by 244
Self-citationDaniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231
Self-citationIncidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208
Self-citation
Cited by
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationPituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Pivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citationFleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30313-4 · Cited by 101
Self-citation
Metadata
- Authors
- Feelders, R. A., Newell-Price, J., Pivonello, R., Nieman, L. K., Hofland, L. J., & Lacroix, A.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 7
- Issue
- 4
- Pages
- 300-312
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2884107160
- Cited by
- 154
- References
- 17
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the medical treatment of Cushing's syndrome. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30155-4
- The paper
- Feelders, R. A., Newell-Price, J., Pivonello, R., Nieman, L. K., Hofland, L. J., & Lacroix, A. (2019). Advances in the medical treatment of Cushing's syndrome. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30155-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.